CPACS: Research, Results, Market Comparisons, and Valuations, page-242

Was it a good investment for AbbVie? Perhaps the $30billion that they are reported to have made to date from the drug has paid back their investment?

They paid for a derisked asset: in 2015, the drug was already FDA approved! Jensen went in early post Phase 2, so they deserve greater success. And the early investors too deserved greater payouts.

Anyway, it turns out one of the challengers drug, Biogen's Brukinsa, proved superior over Imbruvica in a head-to-head trial in some indications! That will hurt!

Perhaps where things seem to fall is: What would be the remaining value of the company that AbbVie bought once this one asset is stripped off them? There appears to be nothing else - but maybe the success of this one just overshadows all else? I don't know.

There are lessons and questions for me as a RAC holder!
a) Once you find the one, get in early, best before licensing deals, and hang in there even during the turbulence. From $5 to $261 must have been quite a ride for those who were on board!
b) Licensing is an option - we will need to fund Ph 3 trials and the rest (unless we get bought before that).
c) Speed helps. I know we are moving at the speed of science, but I just wish we could move a bit quicker and get the drug in use before someone else comes up with some other cardio-protective pill! Thats selfish me speaking!
d) One asset company? But, looking at the potential indications via the reported synergistic effects, in addition to its cardio-protective effects, is heart-warming.